Hemoglobin · 2008 · 10 citations · 17 references
MedicineCardiologyPharmacologyCancer PharmacologyChemotherapyClinical PharmacologyAnthracycline CardiotoxicityCancer Therapy-related CardiotoxicityCardiovascular Drug SafetyCardiovascular PharmacodynamicsChelation TherapyAnthracycline-induced CardiotoxicityAnthracycline-induced Left Ventricular DysfunctionCardioprotective TherapyCardiovascular Drug ToxicityChronic Cardiac ToxicityDaunorubicin Cardiotoxicity
The risk of cardiotoxicity is the main drawback of anthracycline antibiotics. However, these drugs remain among the most effective and frequently used anti cancer drugs. In this study we aimed to assess the cardioprotective effects of aroylhydrazone iron (FE) chelators: pyridoxal isonicotinoyl hydrazone (PIH) and its two analogs: salicyladehyde isonicotinoyl hydrazone (SIH) and pyridoxal o-chlorbenzoyl hydrazone (o-108). In rabbits, chronic treatment with daunorubicin (DAU) (3 mg/kg weekly for 10 weeks) induced mortality (33%) as well as left ventricular (LV) dysfunction. Co-administrations of PIH (25 mg/kg, i.p.), SIH hydrochloride [1 mg/kg, iv] as well as o-108 (10 mg/kg, i.p.), fully prevented premature deaths and most of the DAU-induced functional impairments were significantly suppressed. However, when 2- to 2.5-fold higher doses of the chelators were used, they led to rather paradoxical and mostly negative results regarding both cardioprotection and overall mortality.
17
Mobilization of iron from reticulocytes
FEBS Letters · 1979 · 196 citations · Full text
Anthracycline-Induced Cardiotoxicity
Radomír Hrdina, Vladimír Geršl, Ivona Klimtová et al. · Acta Medica (Hradec Kralove Czech Republic) · 2000 · 109 citations · Full text
Medicine, Pharmacology, Toxicology +17
Tomáš Šimůnek, Christa Boer, R. Arthur Bouwman et al. · Journal of Molecular and Cellular Cardiology · 2005 · 92 citations · Full text